NCT06677203: A reported trial by Asceneuron S.A.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT06677203 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of ASN51 in Adults With Early Alzheimer's Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 16, 2024 |
| Completion date | Nov. 8, 2024 |
| Required reporting date | Nov. 8, 2025, midnight |
| Actual reporting date | June 13, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |